HTLV is a neglected retrovirus affecting 5-10 million people worldwide, with Brazil having the highest number of cases. About 0.3-3.8% of people living with HTLV (PLwHTLV) develop HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a neurological disorder mainly driven by an exacerbated host immune response. Currently, there are no validated biomarkers available to assess the risk of progression to HAM/TSP. Therefore, this study aimed to evaluate the performance of machine learning models (MLMs) in predicting disease progression among PLwHTLV based on clinical data and ENTPD1 gene polymorphisms, which may play a role in HAM/TSP pathogenesis. Variables with higher predictive impact included clinical features such as motor function, urinary impairment and limb dysfunction, while ENTPD1 variants (rs10748643 and rs11188513) showed minimal contribution. Among the evaluated models, Naive Bayes exhibited the best performance, achieving good sensitivity (Recall: 0.78) and class discrimination (ROC AUC: 0.85; G-Mean: 0.75). However, a low precision (0.45), led to a higher incidence of type I errors. Given that this study focuses on applying MLMs as a screening tool rather than a diagnostic one, this limitation has a minor impact on the intended purpose. Overall, our findings suggest low prognostic potential for rs10748643 and rs11188513 but support the applicability of MLMs based on clinical features to identify individuals at higher risk of disease progression. This strategy could enhance clinical monitoring, enable earlier interventions, and potentially delay neurological decline in PLwHTLV.